A trial looking at diffusion tensor imaging (DTI) to assess brain tumours

Cancer type:

Brain (and spinal cord) tumours
Cancer spread to the brain
Secondary cancers





This trial was looking to see if a new type of scan is useful to assess brain tumours.

Brain tumours are often assessed using magnetic resonance imaging (MRI) scans. MRI scans give a picture of where the tumour is in the brain. This helps doctors to decide which treatment is best, and if it is possible to remove the tumour with an operation.

But MRI scans do not show where the nerve pathways are in the brain. As this doesn’t show up on MRI, doctors cannot be absolutely sure where the nerve pathways and white matter tracts are in relation to the tumour. So one of the risks of having an operation to remove a brain tumour is that a nerve pathway may be damaged.

Diffusion tensor imaging (DTI) is a new type of scan that does show the white matter tracts and the nerve pathways. If surgeons can see where the nerve pathways are compared to the brain tumour, they can plan surgery more accurately and prevent damage to the white matter tracts during the operation.

The aim of this trial was to see if DTI scans are useful for patients due to have an operation to remove a brain tumour.

Summary of results

The research team found that DTI scans are useful for getting a more detailed picture of the brain.

The trial recruited 64 people with brain tumours. They all had an MRI scan and a DTI scan before their operation.

The research team looked at the scans together, and found that they could see white matter tracts, and therefore see where the nerves are. They also found they could see the difference between normal tissue and areas of tumour growth more clearly.

They could also to tell the difference between a glioblastoma that started in the brain and a tumour that spread to the brain from another part of the body (metastases) more clearly.

They concluded that it was early days for this new technique, but that it may be useful for planning treatment in the future.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Chris Clark

Supported by

Cancer Research UK

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 461

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page